RxDoctor Payments Data

Khushboo Baldev, MD

Pain Medicine · Jupiter, FLNPI 1235620519

Payments from drug & device makers

What this record shows

22 manufacturers reported payments, led by Abbott at 31.8% of the total. Reporting peaked in 2023 at $9,938 and has fallen 84.2% since, to $1,573 in 2025. Among pain medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,596in general payments, 2019–2025

Across 282 payments — averaging $76.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$7K
  • Medtronic$6K
  • Biotronik NRO, Inc.$3K
  • Relievant Medsystems, Inc.$936
  • Nevro Corp.$801
  • SPR Therapeutics, Inc$610
  • plus $3K from 16 others

What the payments were for

  • Travel & lodging$9,10542%
  • Food & beverage$12,49058%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,596 in reported general payments places this provider in the 90th percentile of 596 pain medicine providers in Florida.

See all pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$285,066
Medicare patients
196
Services billed
4,568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MovantikNaloxegol Oxalate44$17,359
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen539$16,976
ZtlidoLidocaine14$8,870
Pregabalin322$7,182
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen301$6,846
Oxycodone Hcl182$3,803
Tizanidine Hcl335$2,750
Gabapentin156$1,653
Duloxetine Hcl63$1,516
Tramadol Hcl126$1,344
Celecoxib40$1,299
Methadone Hcl78$1,149
Hydromorphone Hcl37$868
Morphine Sulfate37$584
Acetaminophen-CodeineAcetaminophen With Codeine19$497

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Scilex Pharmaceuticals Inc.Ztlido$106$8,87014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 596 pain medicine providers in Florida.

Other pain medicine in Jupiter

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →